3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
4
Pheochromocytoma
2
Paraganglioma
2
Thymoma
1
Sarcoma, Synovial
1
Recurrence
1
Osteosarcoma
1
Neuroblastoma
1
Mesothelioma
1
Meningioma
1
Medulloblastoma
1
Glioma
1
Glioblastoma
1
Esthesioneuroblastoma, Olfactory
1
Ependymoma
1
EGFR-Mutated Non-Small-Cell Lung Carcinoma
1
Carcinoid Tumor
1
Adrenal Gland Neoplasms
1
Adrenal Cortex Neoplasms
1
Interventions
vandetanib
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
sargramostim
1
pentetreotide
1
olaparib
1
lutetium Lu 177 dotatate
1
entinostat
1
aldesleukin
1
Surgical Procedures, Operative
1
Semaxinib
1
Ritonavir
1
Radiotherapy
1
Photochemotherapy
1
Paclitaxel
1
Indinavir
1
Gefitinib
1
Fentanyl
1
Docetaxel
1
Congresses as Topic
1
2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a
1
1-phenyl-3,3-dimethyltriazene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esthesioneuroblastoma, Olfactory
×
olaparib
×
Endocrine
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled